Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 25, 2026

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

[Alemtuzumab in early multiple sclerosis]

Joep Killestein, Chris H Polman

    Nederlands Tijdschrift Voor Geneeskunde
    |February 10, 2009
    PubMed
    Summary

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: Jun 25, 2026

    Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
    09:41

    Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

    Published on: January 20, 2023

    Related Concept Videos

    Multiple Sclerosis l: Introduction01:19

    Multiple Sclerosis l: Introduction

    Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab.

    European journal of neurology·2026
    Same author

    Mediation Analysis Between Brain Age, Disease-Modifying Factors, and Disability and Cognitive Performance in Multiple Sclerosis.

    Neurology·2026
    Same author

    Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis.

    Frontiers in immunology·2026
    Same author

    Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increased risk of infusion-related reactions.

    Multiple sclerosis journal - experimental, translational and clinical·2026
    Same author

    Glial Fibrillary Acidic Protein and Neurofilament Light Reference Intervals in Healthy Individuals.

    JAMA network open·2026
    Same author

    Predictors of B-cell repopulation in people with multiple sclerosis treated with ocrelizumab: insights from two large cohorts.

    Journal of neurology, neurosurgery, and psychiatry·2026